CDMO

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Hancock Richard BDirector $70k10k shares OtherFeb 5, 2025 $714.0K102.7k shares $6.95 --
Ziebell Mark RV. P., General Counsel $336k55.3k shares OtherFeb 5, 2025 $595.6K98.1k shares $6.07 --
Hart Daniel RChief Financial Officer $712k125.9k shares OtherFeb 5, 2025 $588.6K104k shares $5.66 --
Green Nicholas StewartDirector, Officer: President & CEO $075k shares OtherFeb 5, 2025 $544.5K75k shares $7.26 --
Hart Daniel RChief Financial Officer $071.1k shares OtherFeb 5, 2025 $494.3K71.1k shares $6.95 --
Ziebell Mark RV. P., General Counsel $055.3k shares OtherFeb 5, 2025 $384.4K55.3k shares $6.95 --

News

prnewswire.comScinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiativesprnewswire.comJun 10

gurufocus.comMEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.gurufocus.comJun 4

prnewswire.comScinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facilityprnewswire.comMay 20

globenewswire.comPropanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patientsglobenewswire.comMay 19

newsfilecorp.comBioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Updatenewsfilecorp.comMay 14

Trade CDMO

About Avid Bioservices, Inc.

Avid Bioservices, Inc. operates as a Contract Development and Manufacturing Organization (CDMO), specializing in the development and CGMP-compliant production of biopharmaceutical drug substances. Their core expertise lies in compounds derived from mammalian cell culture, providing both clinical and commercial scale manufacturing solutions. The company is proficient in producing critical therapeutics such as monoclonal antibodies and recombinant proteins. Beyond manufacturing, their comprehensive service portfolio encompasses CGMP manufacturing for drug substances, bulk packaging, rigorous release and stability testing, and essential regulatory submission and support. Additionally, Avid Bioservices offers a range of process development services, including the optimization of upstream and downstream processes, alongside the development, testing, and characterization of analytical methods. Avid Bioservices primarily serves clients within the biotechnology and biopharmaceutical industries. The company, which was originally incorporated in 1981, was known as Peregrine Pharmaceuticals, Inc. before officially rebranding to Avid Bioservices, Inc. in January 2018. Its corporate headquarters are situated in Tustin, California.

CEO: Nicholas Stewart Green MBA
IPO Date: Apr 4, 1994

Market Data

Open: $12.49
High: $12.49
Low: $12.49
Volume: 0
52W High: $12.51
52W Low: $5.90

Valuation

Market Cap: $799M
Enterprise Value: $969M

Financials

Free Cash Flow: $-21M
Revenue: $140M
Net Income: $-141M
Cash: $38M
Debt: $208M

Events

EarningsDec 10

EPS est. -0.12 · actual -0.27